These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
551 related articles for article (PubMed ID: 32910349)
21. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y; J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025 [TBL] [Abstract][Full Text] [Related]
22. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Goenka L; Padmanaban R; George M Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201 [TBL] [Abstract][Full Text] [Related]
23. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. Wish JB; Pergola P Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502 [TBL] [Abstract][Full Text] [Related]
26. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD; Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204 [TBL] [Abstract][Full Text] [Related]
27. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B; Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784 [TBL] [Abstract][Full Text] [Related]
28. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease. Li P; Cui Y; Xu X; Dong J; Liao L Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621 [TBL] [Abstract][Full Text] [Related]
29. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management. Beavers CJ Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052 [TBL] [Abstract][Full Text] [Related]
30. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease? Doggrell SA Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251 [No Abstract] [Full Text] [Related]
31. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems. Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508 [TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives. Sarafidis PA; Memmos E; Alexandrou ME; Papagianni A Curr Pharm Des; 2018; 24(46):5528-5536. PubMed ID: 30848187 [TBL] [Abstract][Full Text] [Related]
33. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease. Shah M; Awad AS; Abdel-Rahman EM J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929 [TBL] [Abstract][Full Text] [Related]
34. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. Epstein M Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953 [TBL] [Abstract][Full Text] [Related]
35. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM; JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557 [TBL] [Abstract][Full Text] [Related]
36. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A; Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027 [TBL] [Abstract][Full Text] [Related]
37. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. Kobayashi M; Girerd N; Zannad F Nephrol Dial Transplant; 2024 Jun; 39(7):1063-1072. PubMed ID: 38192033 [TBL] [Abstract][Full Text] [Related]
38. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275 [TBL] [Abstract][Full Text] [Related]
39. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease. Verma A; Patel AB Trends Endocrinol Metab; 2021 May; 32(5):261-263. PubMed ID: 33637415 [TBL] [Abstract][Full Text] [Related]
40. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1. Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]